Advertisement

International Journal of Hematology

, Volume 83, Issue 1, pp 66–73 | Cite as

Adoptive Transfer of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes for the Treatment of Angiocentric Lymphomas

  • Eun-Kyung Kim
  • Sung-Hee Yoon
  • Hyun-Il Cho
  • Tai-Gyu Kim
  • Young Seon Hong
  • Myung Ah Lee
  • Chun-Choo Kim
Article

Abstract

Angiocentric lymphoma, known as natural killer (NK)/T-cell non-Hodgkin’s lymphoma, has been reported to be associated with the Epstein-Barr virus (EBV). We performed adoptive transfer of EBV-specific polyclonal T-cell lines in 3 patients with extranodal NK/T-cell lymphoma, nasal type, and evaluated the treatment for safety, immunologic reconstitution, and clinical outcomes. The tissue samples collected from the 3 patients were confirmed by polymerase chain reaction analysis to be EBV positive. In the cases of the first and second patients, EBV-transformed B-lymphoblastoid cell lines (LCLs) and T-cell lines were generated from peripheral lymphocytes of HLA-matched sibling donors. The third patient’s T-cell lines were induced with autologous lymphocytes. Polyclonal T-cell infusion was carried out after high-dose radiotherapy because active relapsed disease remained in all of the patients. The first patient received 4 weekly infusions of 2 X 107 cells/m2, and the second and third patients underwent treatment with 2 cycles of infusions of the same dosage. All T-cell lines showed >60% NK activity, cytotoxic T-lymphocyte (CTL) responses of >40% against autologous LCLs, and no CTL activity against patient-derived lym-phoblasts. The level of cytotoxicity increased substantially in all patients after cell infusion. The 2 patients who received T-cell therapy twice had stabilized disease for more than 3 years. These safe treatments exhibited no severe inflammatory response, and no serious toxicity developed during T-cell therapy. Our findings demonstrate that adoptively transferred cells may provide reconstitution of EBV-specific CTL responses in patients with active relapsed angiocentric lymphoma. These results provide a rationale for the immunotherapy of angiocentric lymphoma.

Key words

Angiocentric lymphomas Epstein-Barr virus Cytotoxic T-lymphocyte Adoptive transfer Cancer immunotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fechner RE, Lampin DW. Midline malignant reticulosis. Arch Otolaryngol. 1972;95:467–476.CrossRefPubMedGoogle Scholar
  2. 2.
    Jaffe ES. Pathologic and clinical spectrum of post-thymic T-cell malignancies. Cancer Invest. 1984;2:413–426.CrossRefPubMedGoogle Scholar
  3. 3.
    Lipford EH, Margolick JB, Longo DL, Fauci AS, Jaffe ES. Angio-centric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferation. Blood. 1988;72:1674–1681.PubMedGoogle Scholar
  4. 4.
    Medeiros LJ, Peiper SC, Elwood L, Yano T, Raffeld M, Jaffe ES. Angiocentric immunoproliferative lesions: a molecular analysis of eight cases. Hum Pathol. 1991;22:1150–1157.CrossRefPubMedGoogle Scholar
  5. 5.
    Ho FC, Srivastava G, Loke SL, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and ‘T’ cell type. Hematol Oncol. 1990;8:271–281.CrossRefPubMedGoogle Scholar
  6. 6.
    Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/ leukemia: pathology and treatment. Hematol Oncol. 1997;15:71–79.CrossRefPubMedGoogle Scholar
  7. 7.
    Aviles A, Rodriguez L, Guzman R, Talavera A, Garcia EL, Diaz-Maquero JC. Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate. Hematol Oncol. 1992;10:141–147.CrossRefPubMedGoogle Scholar
  8. 8.
    Ferry JA, Sklar J, Zukerberg LR, Harris NL. Nasal lymphoma: a clinicopathologic study with immunophenotypic and genotypic analysis. Am J Surg Pathol. 1991;15:268–279.CrossRefPubMedGoogle Scholar
  9. 9.
    Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103–111.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hema-tolymphoreticular Study Group of the Korean Society of Patholo-gists. Revised European-American lymphoma. Cancer. 1998;83: 806–812.CrossRefPubMedGoogle Scholar
  12. 12.
    Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol. 1992;3:297–307.PubMedGoogle Scholar
  13. 13.
    Magrath I, Jain V, Bhatia K. Epstein-Barr virus and Burkitt’s lymphoma. Semin Cancer Biol. 1992;3:285–295.PubMedGoogle Scholar
  14. 14.
    Thomas JA, Allday MJ, Crawford DH. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res. 1991;57:329–380.CrossRefPubMedGoogle Scholar
  15. 15.
    Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lym-phoproliferation. Lancet. 1995;345:9–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551–555.CrossRefPubMedGoogle Scholar
  17. 17.
    Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997;157:217–222.CrossRefPubMedGoogle Scholar
  18. 18.
    Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549–1555.PubMedGoogle Scholar
  19. 19.
    Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin’s disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998;9:S129-S132.CrossRefPubMedGoogle Scholar
  20. 20.
    Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood. 1998;91: 2925–2934.PubMedGoogle Scholar
  21. 21.
    Chua D, Huang J, Zheng B, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94:73–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Comoli P, de Palma R, Siena S, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004;15:113–117.CrossRefPubMedGoogle Scholar
  23. 23.
    Lucas KG, Salzman D, Garcia A, et al. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lym-phocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004;100:1892–1901.CrossRefPubMedGoogle Scholar
  24. 24.
    Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105:1898–1904.CrossRefPubMedGoogle Scholar
  25. 25.
    Sadler AM, Petronzelli F, Krausa P, et al. Low-resolution DNA typing for HLA-B using sequence-specific primers in allele- or group-specific ARMS/PCR. Tissue Antigens. 1994;44:148–154.CrossRefPubMedGoogle Scholar
  26. 26.
    Tiercy JM, Jeannet M, Mach B. A new approach for the analysis of HLA class II polymorphism: ‘HLA oligotyping.’ Blood Rev. 1990; 4:9–15.CrossRefPubMedGoogle Scholar
  27. 27.
    Cho HI, Kim HJ, Oh ST, Kim TG. In vitro induction of carcinoem-bryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine. 2003;22:224–236.CrossRefPubMedGoogle Scholar
  28. 28.
    Cuadra-Garcia I, Proulx GM, Wu CL, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol. 1999;23:1356–1369.CrossRefPubMedGoogle Scholar
  29. 29.
    Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clini-copathological features and prognosis. Br J Haematol. 1997;97: 821–829.CrossRefPubMedGoogle Scholar
  30. 30.
    Liang R, Chen F, Lee CK, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant. 1997;19:91–93.CrossRefPubMedGoogle Scholar
  31. 31.
    Nawa Y, Takenaka K, Shinagawa K, et al. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:1321–1322.CrossRefPubMedGoogle Scholar
  32. 32.
    Takenaka K, Shinagawa K, Maeda Y, et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma. 2001;42:1297–1303.CrossRefPubMedGoogle Scholar
  33. 33.
    Okamura T, Kishimoto T, Inoue M, et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lym-phoproliferative disease. Bone Marrow Transplant. 2003;31: 105–111.CrossRefPubMedGoogle Scholar
  34. 34.
    Frisan T, Sjoberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin’s disease. Blood. 1995;86:1493–1501.PubMedGoogle Scholar
  35. 35.
    Sing AP, Ambinder RF, Hong DJ, et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin’s disease. Blood. 1997;89:1978–1986.PubMedGoogle Scholar
  36. 36.
    Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin’s disease patients: implications for a T-cell-based therapy. Cancer Res. 2001; 61:6219–6226.PubMedGoogle Scholar
  37. 37.
    Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001;61:261–269.CrossRefPubMedGoogle Scholar
  38. 38.
    Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436–442.CrossRefPubMedGoogle Scholar
  39. 39.
    Trinchieri G Biology of natural killer cells. Adv Immunol. 1989;47: 187–376.CrossRefPubMedGoogle Scholar
  40. 40.
    Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol. 1997;71:267–275.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989;320: 1731–1735.CrossRefPubMedGoogle Scholar
  42. 42.
    Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2:850–861.CrossRefPubMedGoogle Scholar
  43. 43.
    Wheatley GH 3rd, McKinnon KP, Iacobucci M, Mahon S, Gelber C, Lyerly HK. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of post-transplantation lymphoma. Surgery. 1998;124:171–176.CrossRefPubMedGoogle Scholar
  44. 44.
    Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188: 1359–1368.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Munz C. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8+ killer T cells. J Exp Med. 2001;193:405–411.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin’s lymphoma. Int J Cancer. 2001;93:706–713.CrossRefPubMedGoogle Scholar
  47. 47.
    Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003; 101:1905–1912.CrossRefPubMedGoogle Scholar
  48. 48.
    Bollard CM, Straathof KC, Huls MH, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004;27:317–327.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Eun-Kyung Kim
    • 1
  • Sung-Hee Yoon
    • 1
  • Hyun-Il Cho
    • 1
    • 2
  • Tai-Gyu Kim
    • 1
    • 2
  • Young Seon Hong
    • 3
  • Myung Ah Lee
    • 3
  • Chun-Choo Kim
    • 1
    • 3
  1. 1.Department of Microbiology and Immunology, Catholic Research Institute of Medical Science, College of MedicineThe Catholic University of KoreaSeocho-Ku, SeoulKorea
  2. 2.Hemopoietic Stem Cell BankThe Catholic University of KoreaSeocho-Ku, SeoulKorea
  3. 3.Division of Oncology, Department of Internal Medicine, Clinic Institute of St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulKorea

Personalised recommendations